Pegylated Liposomal Doxorubicin Sets New Standard in Refractory Desmoid Tumors: Phase 3 Trial Insights

A Paradigm Shift in Desmoid Tumor Management

For decades, the management of desmoid tumors (DTs)—also known as aggressive fibromatosis—has been a clinical conundrum. While histologically benign and non-metastasizing, these mesenchymal neoplasms are characterized by an unpredictable clinical course, local invasiveness, and a high propensity for recurrence. The treatment landscape has shifted from aggressive surgical resection, which often led to high morbidity and recurrence rates, toward more conservative ‘watch-and-wait’ strategies and systemic interventions. However, for patients with advanced, symptomatic, or refractory disease, the need for effective and tolerable systemic therapy remains acute.

A landmark Phase 3 investigator-initiated trial, recently published in Clinical Cancer Research, provides compelling evidence for the efficacy of pegylated liposomal doxorubicin (PLD) in this patient population. Led by Xu et al., the study demonstrates that PLD offers a dramatic improvement in progression-free survival (PFS) and objective response rates, potentially establishing it as a preferred systemic option for patients who have failed prior therapies or require rapid disease control.